Candida auris infection spreads rapidly in hospitals
Candida auris infection
Candida auris, a multidrug-resistant fungus, infects critically ill people using invasive medical equipment in hospitals and long-term care facilities. Many strains resist antifungals, making it difficult to treat bloodstream, wound, ear, and urinary infections.
What is Candida auris?
- Candida auris, discovered in 2009, is now a global infectious disease.
- It spreads rapidly in hospitals and can survive on surfaces for weeks.
- This Candida species does not reside on the body; infections mainly occur from contaminated surfaces or colonized people.
Symptoms
- High fever, chills, low blood pressure, and rapid heart rate are symptoms of bloodstream infections.
- Wound infections: redness, swelling, and discomfort.
- Pain, pressure, or fullness from ear infections.
- Colonization without symptoms: patients may unwittingly transmit C. auris on their skin.
Possible Risks
- Patients with CVCs, catheters, breathing, or feeding tubes.
- People with diabetes, blood malignancies, or immunological deficiencies.
- Recent surgery or long hospital stays.
- Excessive antibiotic usage.
Treatment
- Treatment begins with echinocandin antifungals.
- Combination therapy or novel antifungals are needed for strains that resist all three classes.
- Infected individuals had 30% to 60% mortality, but many had severe underlying illnesses.
Prevention
- Hospitals' strict hand and surface hygiene.
- Screening and isolating colonised patients to prevent epidemics.
- Use antibiotics and intrusive devices carefully.
- Before hospital visits, inform doctors about C. auris infections.
What causes Candida auris?
Candida auris is caused by a yeast (fungus) that does not naturally inhabit the body. In healthcare settings, it is mainly spread by contaminated surfaces, equipment, or infected/colonized patients. It's not flying.
Candida auris development
- Infection by Candida auris in the bloodstream, wounds, or other body sites is the cause.
- Human flora usually does not contain C. auris, unlike other Candida species.
- Bedrails, doorknobs, and medical devices are its habitat in hospitals.
Paths of Transmission
- Plastic, metal, and textiles can harbour the fungus for weeks.
- Catheters, central venous lines, and breathing or feeding tubes allow access.
- Personal contact: C. auris-colonised individuals can transmit it without exhibiting symptoms.
- According to experts, it does not travel through the air.
Possible Risks
- Poor immune system (e.g., cancer, diabetes, organ transplant).
- Recent surgery or long hospital stays.
- Regular antibiotic or antifungal treatment alters microbial equilibrium.
- Medical intervention via tubes or catheters.
Quick Table: Cause/Risk
- Candida auris yeast: Infection causation
- Surface contamination: Transmission source
- Medical devices: Bloodstream entry
- Patient colonisation: Symptomless
- Less immunity: More susceptible.
Anyone killed by Candida auris?
Candida auris kills worldwide. In critically ill or immunocompromised patients, this fungus causes 30% to 60% bloodstream infections (candidemia) that kill. A 2025 worldwide investigation indicated that almost half of C. auris bloodstream infection patients died within 30 days.
Key Candida auris Death Statistics
- Although many infected individuals had severe underlying illnesses, studies report 30–60% mortality.
- Global outbreaks: US, European, Asian, and African hospitals have reported deaths. A recent 2025 study: 91 of 162 C. auris bloodstream infection patients (56.2%) died within 30 days.
- ICU stays, central venous catheters, abdominal surgery, poor antifungal access, and decreased immunity increase the risk.
Why It Kills
- Some strains resist fluconazole and all three main antifungals.
- Misidentification as other Candida species delays treatment.
- Hospital spread: Lasts weeks on surfaces, making outbreaks difficult to prevent.
Cure Candida auris?
Many Candida auris strains are resistant to antifungals, making treatment difficult.
Treat and Cure
- The primary treatment is echinocandin antifungals.
- In cases of resistance, doctors may use amphotericin B or azole antifungals, often together.
- A new antifungal called ibrexafungerp is being explored for resistant instances.
- Delays in diagnosis or drug resistance can reduce therapy efficacy.
Challenges
- Multidrug resistance: Some strains resist all three antifungals.
- Misidentification: Labs may misidentify C. auris as other Candida species, delaying therapy.
- Hospital outbreaks: The fungus can spread after treating one patient.
Test for Candida auris
- Major Testing Methods
- Real-time PCR
- Fastest and most accurate colonization detection.
- Commonly used on axilla and groin swabs.
- Gives findings in hours for rapid infection control.
MS MALDI
- Laser desorption/ionization time-of-flight mass spectrometry with a matrix.
- The protein profile identifies C. auris.
- Databases must be updated to avoid misidentification.
Culture-based techniques
- Chromogenic Candida agar or enrichment broth-incubated swabs.
- Slower (days) and confused with other Candida species.
- Still, it is the diagnostic gold standard, but its turnaround time is a limitation.
Biochemical tests
- Updated platforms distinguish C. auris from relatives.
- However, they are not as reliable as PCR or MALDI-TOF.
Testing Challenges
- Many mistake C. auris for Candida haemulonii or other species.
- Its phenotype is identical to that of other Candida under a microscope.
- PCR and MALDI-TOF labs are needed in some hospitals.
- Standards for antifungal susceptibility testing are being developed, but they are essential for therapy.
Major Treatment Obstacles
- Multiple-drug resistance
- Several strains resist fluconazole, echinocandins, and amphotericin B.
- Pan-resistance instances (resistant to all major antifungals) are rising.
- Few drug options
- First-line fungistatic echinocandins halt growth.
- Resistance or toxicity typically defeats amphotericin B and triazoles.
- New medications like ibrexafungerp, fosmanogepix, and rezafungin show promise but lack massive clinical evidence.
Biofilm formation
- C. auris biofilms on medical devices make antifungals less effective.
- Biofilms increase relapse and persistence.
Continued colonization
- Patients are often colonised for months or years after treatment.
- Hospitalised colonised patients can silently spread fungus.
Delays in diagnosis
- Misidentification as other Candida species slows treatment.
- Not all hospitals have PCR or MALDI-TOF.
Table of Treatment Limitations.
- Standard antifungals are less effective due to drug resistance.
- Very few safe and effective alternatives
- Biofilm: Guards fungus from medications
- Hospital dissemination and reinfection linger
- Delayed diagnosis: Poor treatment.
Trade-offs, risks
- Toxicity: Amphotericin B might damage the kidneys and create serious adverse effects.
- Unfortunately, successful treatment may not remove colonization.
- Hospital outbreaks: Contaminated surfaces and equipment require strict infection control.
- Resistance evolution: Antifungal overuse accelerates resistance.
Latest Candida auris antifungals
Recent Candida auris antifungals, including rezafungin, fosmanogepix, and ibrexafungerp, are promising against resistant strains. Rezafungin is given weekly; fosmanogepix targets a novel fungal enzyme; and ibrexafungerp is taken orally and works against pan-resistant strains.
Future Antifungals
- Rezafungin has been FDA-approved for the treatment of candidemia and invasive candidiasis since 2023.
- Echinocandin II, once weekly.
- Strong activity in all C. auris clades.
- Long half-life and adequate tissue dispersion.
- Limitation: FKS mutations can cause resistance.
Fosmanogepix
- Manogepix prodrug, a novel antifungal class.
- Disrupts fungal cell walls by inhibiting Gwt1.
- Effective against pan-resistant isolates.
- Early clinical trial: 89% C. auris candidemia survival at 30 days.
Ibrexafungerp
- Vulvovaginal candidiasis-approved oral triterpenoid.
- It binds to β-1,3-D-glucan synthase differently from echinocandins.
- MICs range from 0.25 to 2 μg/mL, indicating limited cross-resistance.
- Small study: 7 of 8 ibrexafungerp-treated candidemia patients survived.
Issues and Considerations
- Over time, new medications may develop resistance.
- Clinical data are scarce: Most is from short trials or case reports.
- Combination therapy: Echinocandins and amphotericin B may treat resistant patients.
- Access issues: Newer medications vary by country and may be expensive.
CONCLUSION
Candida auris is a global health threat because it is resistant to antifungals, spreads easily in hospitals, and is difficult to detect in labs. Echinocandins are the first-line treatment; however, rezafungin, fosmanogepix, and ibrexafungerp may work against resistant strains.
Candida auris is treatable but difficult to maintain, requiring antifungal medication and severe infection control. Its increase underlines the need for new antifungals, quick diagnostics, and global cooperation to prevent hospital outbreaks.







